Vaccinex, Inc. (VCNX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol VCNX
- Company Vaccinex, Inc.
- Price $0.7
- Changes Percentage -30
- Change -0.3
- Day Low $0.61
- Day High $0.8
- Year High $8.9
- Year Low $0.61
- Market Cap $1,873,648
- Price Avg 50 EMA (D) $1.07
- Price Avg 200 EMA (D) $3.75
- Exchange NASDAQ
- Volume 10,724
- Average Volume 19,833
- Open $0.78
- Previous Close $1
- EPS 7.42
- PE 0.09
- Earnings Announcement 2025-03-31 12:30:00
- Shares Outstanding $2,676,640
Company brief: VACCINEX, INC. (VCNX )
- Healthcare
- Biotechnology
- Dr. Maurice Zauderer Ph.D.
- https://www.vaccinex.com
- US
- N/A
- 08-09-2018
- US9186403013
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.